Pharmaceutical

Risk adjusted net present value: What is the current valuation of AstraZeneca’s Saruparib?

Saruparib is a small molecule commercialized by AstraZeneca, with a leading Phase III program in Metastatic Prostate Cancer.

Mar 13, 2024 - 18:29
Saruparib is a small molecule commercialized by AstraZeneca, with a leading Phase III program in Metastatic Prostate Cancer.
Read the original article

Tags:

Previous Article

Eli Lilly’s Lebrikizumab Shows Promise in Eczema Treatment for Skin of Color

Next Article

Risk adjusted net present value: What is the current valuation of AstraZeneca’s ...

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

First-in-class migraine treatment Vydura approved for NHS Scotland

First-in-class migraine treatment Vydura approved for N...

May 10, 2023

Accenture invests in Earli to advance early cancer detection tech

Accenture invests in Earli to advance early cancer dete...

Aug 21, 2024

ProMED, an early warning system on disease outbreaks, appears near collapse

ProMED, an early warning system on disease outbreaks, a...

Aug 3, 2023